Global market for oligos exceeds $700 million

Total spending by research scientists on synthetic DNA oligonucleotides (oligos) is over US$700 million annually

Register for free to listen to this article
Listen with Speechify
ARLINGTON, Va.—According to the findings of a new report from BioInformatics LLC, total spend­ing by research scientists on synthetic DNA oligonucleotides (oligos) is over US$700 million annually.
In the last decade, the demand for high quality oligonucleotides has risen with the focus on micro­array technologies and antisense clinical research. Oligos represent a lucrative market for life science suppliers because these tools are critical to a wide variety of research applications and they are constantly being consumed with each experiment performed.
Because the overall market for oligos is considered mature, sup­pliers are challenged to distinguish their brand from the many others available to scientists.
BioInformatics—a market research and consulting firm—recently sur­veyed over 700 scientists who use synthetic oligos in their research. The results of this sur­vey are presented in a new report, The Global Market for Synthetic Oligonucleotides.
This report follows a 2004 report, The U.S. Market for Synthetic Oligonucleotides, allowing the new report to offer some trend comparisons over the past two years.
For DNA oligos, respon­dents identified Integrated DNA Technologies as the dominant sup­plier. The other top suppliers of DNA oligos are Invitrogen, MWG Biotech, Operon Biotechnologies, and Sigma-Genosys (a division of Sigma-Aldrich).
"The exact order of the rank­ing beyond the top spot var­ies depending on which metric you use to look at the market," explains Dr. Tamara Zemlo, direc­tor, Syndicated Research and Analysis for BioInformatics. Some suppliers have a greater share of the market in terms of sales than they do in terms of volume sold, and vice versa. Those suppliers with a relatively greater market share based on sales are able to charge a premium for their oligo services. "Suppliers whose sales shares are much lower than their volume shares should consider ways to take advantage of their market share position to raise their prices."

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN Magazine May 2024

Latest Issue  

• Volume 20 • Issue 3 • May 2024

May 2024

May 2024 Issue